ArticleDiagnostic and interventional radiology (Ankara, Turkey)2022
Application of radiomics in predicting the preoperative risk stratification of gastric stromal tumors.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- Intratumoral and Peritumoral Radiomics based on Contrast-enhanced CT Images: Biomarkers to Predict the Risk-Grade of Gastrointestinal Stromal TumorsCurrent medical imaging · 2026Article
- Different radiomics models in predicting the malignant potential of small intestinal stromal tumors.European journal of radiology open · 2024Article
- From pixels to prognosis: Imaging biomarkers for discrimination and outcome prediction of pulmonary embolism : Original Research Article.Emergency radiology · 2024Article
- Prediction of High-Risk Gastrointestinal Stromal Tumor Recurrence Based on Delta-CT Radiomics Modeling: A 3-Year Follow-up Study After Surgery.Clinical Medicine Insights. Oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PURPOSE The stomach is the most common site of gastrointestinal stromal tumors (GISTs). In this study, clinical model, radiomics models, and nomogram were constructed to compare and assess the clinical value of each model in predicting the preoperative risk stratification of gastric stromal tumors (GSTs). METHODS In total, 180 patients with GSTs confirmed postoperatively pathologically were included. 70% was randomly selected from each category as the training group (n = 126), and the remaining 30% was stratified as the testing group (n = 54). The image features and texture characteristics of each patient were analyzed, and predictive model were constructed. The image features and the rad-score of the optimal radiomics model were used to establish the nomogram. The clinical application value of these models was assessed by the receiver operating characteristic (ROC) curve and decision curve analysis (DCA). The calibration of each model was evaluated by the calibration curve. RESULTS The Area Under the Curve (AUC) value of the nomogram was 0.930 (95% confidence interval [CI]: 0.886- 0.973) in the training group and 0.931 (95% CI: 0.869-0.993) in the testing group. The AUC values of the training group and the testing group calculated by the radiomics model were 0.874 (95% CI: 0.814-0.935) and 0.863 (95% CI: 0.76 5-0.960), respectively; the AUC values calculated by the clinical model were 0.871 (95% CI: 0.811-0.931) and 0.854 (95% CI: 0.76 0-0.947). CONCLUSION The proposed nomogram can accurately predict the malignant potential of GSTs and can be used as repeatable imaging markers for decision support to predict the risk stratification of GSTs before surgery noninvasively and effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.